Nick Glover
Direttore/Membro del Consiglio presso MEI PHARMA, INC.
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Nick Glover
Società | Posizione | Inizio | Fine |
---|---|---|---|
MEI PHARMA, INC. | Direttore/Membro del Consiglio | 11/06/2013 | - |
Independent Dir/Board Member | 11/06/2013 | - | |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Nick Glover
Precedenti posizioni note di Nick Glover
Società | Posizione | Inizio | Fine |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Direttore/Membro del Consiglio | 03/09/2014 | 22/05/2020 |
Amministratore Delegato | 03/09/2014 | 22/05/2020 | |
Presidente | 03/09/2014 | 22/05/2020 | |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Direttore/Membro del Consiglio | 17/01/2011 | 01/02/2013 |
Amministratore Delegato | 01/11/2010 | 01/02/2013 | |
Presidente | 17/01/2011 | 01/02/2013 | |
University Medical Discoveries, Inc.
University Medical Discoveries, Inc. Investment ManagersFinance University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto. | Analista di Private Equity | - | 31/03/2009 |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Direttore/Membro del Consiglio | 01/09/2000 | 01/06/2008 |
Amministratore Delegato | 01/09/2000 | 01/06/2008 | |
Presidente | 01/09/2000 | 01/06/2008 | |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Direttore degli Investimenti | - | - |
Formazione di Nick Glover
University of British Columbia | Graduate Degree |
Simon Fraser University | Doctorate Degree |
University of East Anglia | Undergraduate Degree |
Statistiche
Distribuzione geografica
Canada | 8 |
Stati Uniti | 3 |
Regno Unito | 2 |
Posizioni
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Finance | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MEI PHARMA, INC. | Health Technology |
Aziende private | 6 |
---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
University Medical Discoveries, Inc.
University Medical Discoveries, Inc. Investment ManagersFinance University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto. | Finance |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | Health Technology |
- Borsa valori
- Insiders
- Nick Glover
- Esperienza